▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2047 by analyst upside · 2026-06-27
ARDT
Ardent Health, Inc.
Healthcare · Market Cap $1B · P/E 10.4x
ANALYST PRICE TARGET
+27.5%
implied upside to consensus target
Current Price $9.73
Consensus Target $12.41
Bull Target $14.0
Bear Target $9.0
Analysts Covering 11
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
6
Hold
3
Sell
1
52-Week Low $7.71
52-Week High $15.48
YTD Return +12.6%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) 10.4x
Forward P/E 7.4x
EPS (TTM) $0.94
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $6.4B
Profit Margin 2.1%
52-WEEK RANGE
52-Week Low $7.71
52-Week High $15.48
Current Price $9.73
Bear Target $9.0
Bull Target $14.0
● Now $9.73 ● Target $12.41
TRADING DATA
Avg Volume 474K
YTD Return +12.6%
Analyst Count 11
Consensus Buy
Upside to Target +27.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Ardent Health, Inc. (ARDT) is currently trading at $9.73 with a Wall Street consensus price target of $12.41, implying potential upside of 27.5% over the next 12 months. 11 analysts currently cover ARDT, with a consensus rating of Buy — 64% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $9.0.

ARDT operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 12.6% year-to-date and is currently trading near the lower end of its 52-week range of $7.71 – $15.48.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

INSP +11.4%
Inspire Medical Systems, Inc.
$1B · P/E 9.9x · Hold
PAHC +43.9%
Phibro Animal Health Corporation
$1B · P/E 13.7x · Hold
NUTX +41.5%
Nutex Health Inc.
$1B · P/E 12.2x · Buy
COLL +48.5%
Collegium Pharmaceutical, Inc.
$1B · P/E 17.8x · Buy
ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ARDT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS — Reiterated
Buy → Buy 2026-05-07 33% win rate (6 calls)
RBC Capital — Reiterated
Outperform → Outperform 2026-03-10 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-03-06 29% win rate (7 calls)
JP Morgan — Reiterated
Neutral → Neutral 2026-01-20 43% win rate (7 calls)
UBS — Reiterated
Buy → Buy 2025-12-18 33% win rate (6 calls)
Mizuho — Reiterated
Outperform → Outperform 2025-12-18 Building track record
JP Morgan — Reiterated
Neutral → Neutral 2025-11-24 43% win rate (7 calls)
Mizuho — Reiterated
Outperform → Outperform 2025-11-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →